# Libio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/libio

- Industry: Biotechnology
- Headquarters: Wuxi, China
- Website: www.libiotech.com
- Latest round: Series D (Feb 5, 2016)
- Investors on record: 1

## About

Based in Wuxi, China and established in 2007, Libio operates a biotechnology company that focuses on researching and developing biological and tumor detection reagent and equipment. At present, the company has obtained 20 medical device registration certificates, 16 authorized patents, including 8 invention patents, and published more than 30 academic papers.

The company provides blood group serological diagnosis, gene testing products, and tumor diagnosis. The company has carried out research on the treatment of tumors by using the combination of monoclonal antibodies for tumor-specific recognition and tumor therapeutic drugs. It also built a set of cell bank, which can carry out the culture of monoclonal hybridoma cells and produce a variety of mammalian monoclonal antibodies.

## Funding rounds

- Series D, Feb 5, 2016 — TEDA Venture Capital

## Investors

- TEDA Venture Capital (https://capitalatlas.ai/funds/teda-venture-capital) — Series D